Abstract Library

#3973 Clinical value of endoscopic submucosal dissection combined with chemotherapy for treatment of esophageal neuroendocrine carcinoma

Introduction: Due to the lack of large-scale data describing the clinical and pathological characteristics of esophageal neuroendocrine carcinoma（eNEC), there is no standardized diagnosis and treatment of eNEC currently.

Conference:

Presenting Author:

Authors: Na H, Qi T,

Keywords: Esophageal neuroendocrine carcinoma, Endoscopic submucosal dissection, Chemotherapy,

#3818 Somatostatin analogues or active surveillance in sporadic non-functioning pancreatic neuroendocrine tumors

Introduction: Non-functioning (NF), sporadic, G1-G2 pancreatic neuroendocrine tumors (PanNETs) usually display an indolent course. Surgery is the first-choice treatment for localized tumors >2 cm. Unresectable or metastatic PanNETs expressing somatostatin receptors (SSTRs) are treated with somatostatin analogues (SSAs). The PROMID and the CLARINET studies proved the SSA antiproliferative effect in advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The standard treatment for patients with PanNETs ≤2cm is active surveillance (AS). Yet no evidence of the value of SSA treatment exist in such patient population.

Conference:

Presenting Author: Maratta M

Authors: Maratta M, Chiloiro S, Raia S, Maiorano B, Rossi E,

Keywords: PanNET, somatostatin analogues, efficacy, surveillance, medical treatment,

#3745 Prediction of disease recurrence in patients after complete PanNET G2 resection

Introduction: The number of pancreatic neuroendocrine tumors (PanNETs) detected has been increasing over the past decade. Surgical resection is the only potentially curative treatment for PanNETs, but the risk factors for recurrence are not fully understood, which is of clinical value especially for G2 PanNETs due to their high heterogeneity.

Conference:

Presenting Author:

Authors: Opalinska M, Olearska H, Sowa-Staszczak A, Morawiec-Sławek K, Kurzyńska A,

Keywords: PanNET G2, recurrence risk, NET G2, surgery, PanNET,

#3257 Molecular and functional study of somatostatin receptors in pheochromocytomas and paragangliomas

Introduction: Most pheochromocytomas (PCC) and paragangliomas (PGL) are benign neuroendocrine tumors that overproduce catecholamines causing hypertension, arrhythmia, and stroke; however, 10 30% may present distant metastasis. About 40% are caused by germline mutations, which may be classified in 3 different clusters. PCC/PGL diagnosis involves blood/urine tests and imaging techniques, while their treatment often requires distinct pharmacological and surgical approaches. Thus, identification of new biomarkers for early diagnosis, and progression/response would help to avoid unnecessary tests and enable personalized medicine approaches.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Ibáñez-Costa A

Authors: Ibáñez-Costa A, Blázquez-Encinas R, Alors-Pérez E, Fuentes-Fayos A, Rivero-Cortés E,

Keywords: pheochromocytoma, paraganglioma, somatostatin, somatostatin receptor, neuroendocrine tumor,

#2273 The Clinical Value of Circulating Transcript Analysis (NETest) during Follow-Up of Resected Well-Differentiated Pancreatic Neuroendocrine Tumors

Introduction: Follow-up after resection of pancreatic neuroendocrine tumors (pNET) is designed to detect recurrence early, as incidence is reported up to 48%.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Genc C, Jilesen A, Nieveen van Dijkum E, Klümpen H, Van Eijck C,

Keywords: neuroendocrine, pancreas, recurrence, biomarker, NETest, postoperative follow-up,